Avadel Pharmaceuticals plc Stock News

Thank you, Mr. McHugh, you may begin. As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private

After Leerink Partners and Oppenheimer gave Avadel Pharmaceuticals (NASDAQ: AVDL) a Buy rating last month, the company received another Buy,

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2020 Earnings Conference Call August 10, 2020 08:30 ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jor

Shares of Avadel Pharmaceuticals (NASDAQ:AVDL) decreased 1.3% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 47.83% year over year to ($0.12

* Presented positive topline data from the pivotal Phase 3 REST-ON study * Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with th

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus p

Market forces rained on the parade of Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders today, when the analysts...

Harmony Biosciences has filed to raise $100 million in an IPO, although the final figure will likely differ.

DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10,

Avadel Pharmaceuticals (NASDAQ:AVDL) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday, BidAskClub reports. A number of oth

Equities research analysts expect Avadel Pharmaceuticals PLC (NASDAQ:AVDL) to post earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Four analysts have mad

Today, we take an in-depth look at Avadel Pharmaceuticals which recently sold off its existing product portfolio.

Equillium reports positive data for COVID-19 drug trial. CytoDyn's BLA filing is rejected.

Clinical study to enroll 250 patients from sites that participated in the REST-ON studyStudy to examine the long-term safety and maintenance of efficacy in patients, and.